AmplifyBio Secures $50 Million in Funding to Revolutionize Translational Science and Cell Therapies

AmplifyBio is thrilled to announce a significant funding milestone, having successfully raised $50 million in its latest financing round.

This funding will empower us to further our mission of advancing translational science, cell and gene therapies, and next-generation medicines for the benefit of millions worldwide.

Our unique approach leverages the extensive expertise of our cross-integrated teams and collaborative partners, aiming to bridge the gap between laboratory research and real-world applications.

This capital infusion will be pivotal in enhancing our state-of-the-art facilities, which encompass a fully functional GLP lab spanning 200,000 square feet, specifically tailored for drug development.

The expansion will allow us to explore new therapeutic avenues and refine our pre-clinical models, ensuring that we stay at the forefront of innovation in biotechnology.

At AmplifyBio, we understand the critical importance of turning scientific discoveries into tangible solutions, and this funding will accelerate our efforts to bring groundbreaking treatments to market that address some of the most pressing health challenges facing our society today.

With this robust financial backing, we are more equipped than ever to harness the power of modern science and deliver impactful therapies that hold promise for the future of medicine.

We are excited about the journey ahead and grateful for the support that will enable us to achieve our goals in transforming health outcomes for patients globally.